Program overview
Context
Indication: mCRPC (Metastatic Castration-resistant Prostate Cancer)
Mechanism: Unknown
Modality: Unknown
Sponsor: Minghui Pharmaceutical (Hangzhou)
MHB048C for Injection is flagged as operational burden signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Indication: mCRPC (Metastatic Castration-resistant Prostate Cancer)
Mechanism: Unknown
Modality: Unknown
Sponsor: Minghui Pharmaceutical (Hangzhou)
Registry: 0/5
Timeline: 0/5
Recruitment burden: 3/5
Results availability: 0/5
Program risk: 2/5
https://clinicaltrials.gov/study/NCT07192120
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT07192120 | Low Signal (RECRUITING) | None | Low Signal | large_enrollment_target_signal | few_sites_large_trial_signal | rare_population_signal |